Emerging drugs for eating disorder treatment

Bibliography

• CASPER RD, HEDEKER D, MCCLOUGH JF: Personality dimensions in eating disorder and their relevance for subtyping. J. Am. Acad. Child Adolesc. Psychiatry (1992) 31:830-840.
   PubMed Web of Science ®Google Scholar
• ECKERT ED, HALMI KA, MARCHI P et al.: Ten-year follow-up of anorexia nervosa: clinical course and outcome. Psychol. Med. (1995) 25:143-156.
   PubMed Web of Science ®Google Scholar
• GARNER DM, GARFINKEL PE, O’SHAUGHNESSY M: Validity of the distinction between bulimia with and without anorexia nervosa. Am. J. Psychiatry (1985) 142:581-587.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2004. Practice Guidelines for Eating Disorders, 2nd edn. American Psychiatric Association (2004).
   Google Scholar
• CROW S, BROWN E: Investigational drugs for eating disorders. Expert Opin. Investig. Drugs (2003) 12(3):491-499.
   PubMed Web of Science ®Google Scholar
• SMITH DE, MARCUS MD, LEWIS CE, FITZGIBBON M, SCHREINER P: Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann. Behav. Med. (1998) 20(3):227-232.
   PubMed Web of Science ®Google Scholar
• SMITH DE, MARCUS MD, LEWIS CE et al.: Prevalence of binge eating disorder, obesity, and depression in a biracial cohort of young adults. Ann. Behav. Med. (1998) 20:227-232.
   PubMed Web of Science ®Google Scholar
• DEVLKIN M: Psychotherapy and medication for binge eating disorder, Abstract Plenary Session. International Conference on Eating Disorders. Boston, USA (2002).
   Google Scholar
• DE ZWAAN M: Binge eating disorder and obesity. Int. J. Obes. Relat. Metab. Disord. (2001) 25(Suppl. 1):S51-S55.
   PubMed Web of Science ®Google Scholar
• DSM-IV Eating Disorder. In: Diagnostic and statistical manual of mental disorders (4th edn). RA Vigersky (Ed.), American Psychiatric Association, Washington, DC, USA (1994):539-542.
   Google Scholar
• YANOVSKI SZ, NELSON JE, DUBBERT BK, SPITZER RL: Association of binge eating disorder and psychiatric comorbidity in obese subjects. Am. J. Psychiatry (1993) 150(12):1910.
   Google Scholar
• WONDERLICH S, MITCHELL J, DE ZWAAN M, STEIGER H: In: Eating Disorders Review: Part I. Academy for Eating Disorders, Radcliffe Publising, Oxford, Seattle, USA.
   Google Scholar
• KAYE WH, BULIK CM, THORNTON L, BARBARICH N, MASTERS K: Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am. J. Psychiatry (2004) 161(12):2215-2221.
   PubMed Web of Science ®Google Scholar
• YAGER J, ANDERSEN AE: Clinical practice. Anorexia nervosa. N. Engl. J. Med. (2005) 353(14):1481-1488.
   PubMed Web of Science ®Google Scholar
• O’BRIEN KM, VINCENT NK: Psychiatric comorbidity in anorexia and bulimia nervosa: nature, prevalence, and casual relationships. Clin. Psychol. Rev. (2003) 23(1):57-74.
   PubMed Web of Science ®Google Scholar
• ENGEL SG, CORNELIUSSEN SJ, WONDERLICH SA et al.: Impulsivity and compulsivity in bulimia nervosa. Int. J. Eat. Disord. (2005) 38(3):244-251.
   PubMed Web of Science ®Google Scholar
• DE JONGE PVH, VAN FURTH EF, LACEY JH, WALLER G: The Prevalence of DSM-IV personality pathology among individuals with bulimia nervosa, binge eating disorder and obesity. Psychol. Med. (2003) 33:1311-1317.
   PubMed Web of Science ®Google Scholar
• GRILO CM: Recent research on relationships among eating disorders and personality disorders. Curr. Psychiatry Rep. (2002) 4:14-18.
   Google Scholar
• BULIK CM, SULLIVAN PF, KENDLER KS: Medical and psychiatric morbidity in obese women with and without binge-eating disorder. Int. J. Eat. Disord. (2002) 32:72-78.
   PubMed Web of Science ®Google Scholar
• DOHM FA, STRIEGEL-MOORE RH, WILFLEY DE, PIKE KM, HOOK J, FAIRBURN CG: Self-harm and substance use in a community sample of black and white women with binge-eating disorder or bulimia nervosa. Int. J. Eat. Disord. (2002) 32:389-400.
   PubMed Web of Science ®Google Scholar
• CARTER JC, BLACKMORE E, SUTANDAR-PINNOCK K, WOODSIDE DB: Relapse in anorexia nervosa: a survival analysis. Psychol. Med. (2004) 34:671-679.
   PubMed Web of Science ®Google Scholar
• KAYE WH, NAGATA T, WELTZIN TE et al.: Double-blind, placebo-controlled administration of fluoxetine in restricting and purging-type anorexia nervosa. Biol. Psychiatry (2001) 49:644-652.
   PubMed Web of Science ®Google Scholar
• WALSH BT, KAPLAN AS, ATTIA E et al.: Fluoxetine versus placebo to prevent relapse in anorexia nervosa: primary outcome of drug on time to relapse in 93 weight restored subjects. Presented at: Eating Disorder Research Society. Toronto, ON, USA (2005).
   Google Scholar
• STEINHAUSEN HC: The outcome of anorexia nervosa in the 20th century. Am. J. Psychiatry (2003) 160(4):798.
   Google Scholar
• SULLIVAN PF: Mortality in anorexia nervosa. Am. J. Psychiatry (1995) 152:1073-1074.
   PubMed Web of Science ®Google Scholar
• BACALTCHUK J, HAY P: Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst. Rev. (2003) 4:CD00391.
   Google Scholar
• AGRAS WS, ROSSITER EM, ARNOW B et al.: Pharmacological and cognitive behavioral treatment for bulimia nervosa: a controlled comparison. Am. J. Psychiatry (1992) 149:82-87.
   PubMed Web of Science ®Google Scholar
• LEITENBERG H, ROSEN JC, WOLF J et al.: Comparison of cognitive behavior therapy and desipramine in the treatment of bulimia nervosa. Behav. Res. Ther. (1994) 32:37-45.
   PubMed Web of Science ®Google Scholar
• AGRAS WS: Pharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomes. Psychopharmacol. Bull. (1997) 33:433-436.
   PubMed Web of Science ®Google Scholar
• WALSH BT, HADIGAN CM, DEVLIN MH, GLADIS M, ROOSE SP: Long-term outcome of antidepressant treatment for bulimia nervosa. Am. J. Psychiatry (1991) 148(9):1206-1212.
   PubMed Web of Science ®Google Scholar
• FICHTER MM, KRUGER R, RIEF W, HOLLAND R, DOHNE J: Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J. Clin. Psychopharmacol. (1996) 16(1):9-18.
   PubMed Web of Science ®Google Scholar
• ROMANO SJ, HALMI KA, SARKAR NP, KOKE SC, LEE JS: A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am. J. Psychiatry (2002) 159(1):96-102.
   PubMed Web of Science ®Google Scholar
• ZHU AJ, WALSH BT: Pharmacologic treatment of eating disorders. Can. J. Psychiatry (2002) 47(3):227-234.
   PubMed Web of Science ®Google Scholar
• POWERS PS, SANTANA C: Available pharmacological treatments for anorexia nervosa. Expert Opin. Pharmacother. (2004) 5(11):2287-2292.
   PubMed Web of Science ®Google Scholar
• ROERIG JL, MITCHELL JE, STEFFEN KJ: New targets in the treatment of anorexia nervosa. Expert Opin. Ther. Targets (2005) 9(1):135-151.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, WONDERLICH S, PETERSON C, CROW S: Psychopharmacology of eating disorders: current knowledge and future directions. In: Eating disorders: new directions for research and practice. R Striegel-Moore, L Smolak (Eds), American Psychological Association Press, New York, USA (2001).
   Google Scholar
• GARLAND EJ, REMICK RA, ZIS AP: Weight gain with antidepressants and lithium. J. Clin. Psychopharmacol. (1988) 8(5):323-330.
   PubMed Web of Science ®Google Scholar
• BIEDERMAN J, HERZOG DB, RIVINUS TM et al.: Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. (1985) 5:10-16.
   PubMed Web of Science ®Google Scholar
• ATTIA E, HAIMAN C, WALSH BT, FLATER SR: Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am. J. Psychiatry (1998) 155:548-551.
   PubMed Web of Science ®Google Scholar
• KRAUS T, HAACK M, SCHULD A et al.: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry (1999) 156:312-314.
   PubMed Web of Science ®Google Scholar
• MONDRATY N, BIRMINGHAM C, TOUYZ S et al.: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas. Psychiatry (2005) 13(1):72-75.
   PubMedGoogle Scholar
• ATTIA E, KAPLAN AS, SCHROEDER L, FEDERICI A, STAAB R: Atypical antipsychotic medication in anorexia nervosa. Presented at: Eating Disorders Research Society. Toronto, ON, USA (2005).
   Google Scholar
• BRAMBILLA F, FASSINO S, RAMACCIOTTI C et al.: Psychobiological effects of olanzapine therapy in anorexia nervosa. Presented at: Eating Disorders Research Society. Toronto, ON, USA (2005).
   Google Scholar
• GROSS HA, EBERT MH, FADEN VB et al.: A double-blind control trial of lithium carbonate primary anorexia nervosa. J. Clin. Psychopharmacol. (1981) 6:376-381.
   Google Scholar
• KATZ RL, KEEN CL, LITT IF et al.: Zinc deficiency in anorexia nervosa. J. Adolesc. Health Care (1987) 8:400-406.
   PubMedGoogle Scholar
• LASK B, BRYANT-WAUGH R: Zinc deficiency and childhood-onset anorexia nervosa. J. Clin. Psychiatry (1993) 54:63-66.
   PubMed Web of Science ®Google Scholar
• BIRMINGHAM CL, GOLDNER EM, BAKAN R: Controlled trial of zinc supplementation in anorexia nervosa. Int. J. Eat. Disord. (1994) 15:251-255.
   PubMed Web of Science ®Google Scholar
• GROSS H, EBERT MH, FADEN VB et al.: A double-blind trial of δ9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharamcol. (1983) 3:165-171.
   PubMed Web of Science ®Google Scholar
• MARRAZZI MA, BACON JP, KINZIE J, LUBY ED: Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int. Clin. Psychopharmacol. (1995) 10:163-172.
   PubMed Web of Science ®Google Scholar
• CASPER RC, SCHLEMMER RF, JAVAID JI: A placebo-controlled crossover study or oral clonidine in acute anorexia nervosa. Psychiatry Res. (1987) 20:249-260.
   PubMed Web of Science ®Google Scholar
• HILL K, BUCUVALAS J, MCCLAIN C: Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J. Child Adolesc. Psychopharmacol. (2000) 10:3-8.
   PubMed Web of Science ®Google Scholar
• DOMSTAD PA, SHIH WJ, HUMPHRIES L, DELAND FH, DIGENIS GA: Radionuclide gastric emptying studies in patients with anorexia nervosa. J. Nucl. Med. (1987) 28:816-819.
   PubMed Web of Science ®Google Scholar
• STACHER G, BERGMANN H, WIESNAGROTZKI S et al.: Intravenous cisapride accelerated delayed gastric emptying and increases antral contraction amplitude with primary anorexia nervosa. Gastroenterology (1987) 92:1000-1006.
   PubMed Web of Science ®Google Scholar
• STACHER G, KIOSS A, WIESNAGROTZKI S, BERGMANN H, HOBART J, SCHNEIDER C: Oesophageal and gastric motility disorders in patients categorized as having primary anorexia nervosa. Gut (1986) 27:1120-1126.
   PubMed Web of Science ®Google Scholar
• CRAIGEN D, KENNEDY SH, GARFINKEL PE, JEEJEEBHOY K: Drugs that facilitate gastric emptying. In: The role of drug treatments for eating disorders. PE Garfinkel, DM Garner (Eds), Brunnel/Mazel, New York, USA (1987):161-176.
   Google Scholar
• MOLDOFSKY H, JEUNIEWIC N, GARFINKEL PJ: Primary report of metoclopramide in anorexia nervosa. In: Anorexia nervosa. RA Vigersky (Ed.), Raven Press, New York, USA (1977):373-376.
   Google Scholar
• STACHER G, ABATZI-WENZEL TA, WIESNAGROTZKI S, BERGMANN H, SCHNEIDER C, GAUPMANN G: Gastric emptying, body weight and symptoms in primary anorexia nervosa. Long-term effects of cisapride. Br. J. Psychiatry (1993) 162:398-402.
   PubMed Web of Science ®Google Scholar
• SZMUKLER GI, YOUNG GP, MILLER G, LICHTENSTEIN M, BINNS DS: A controlled trial of cisapride in anorexia nervosa. Int. J. Eat. Disord. (1995) 17:347-357.
   PubMed Web of Science ®Google Scholar
• STROBER M, FREEMAN R, DEANTONIO M, LAMPERT C, DIAMOND J: Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol. Bull. (1997). 33(3):425-431.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, HALMI K, WILSON GT et al.: A randomized secondary treatment study of women with bulimia nervosa who fail to respond to CBT. Int. J. Eat. Disord. (2002) 32(3):271-281.
   PubMed Web of Science ®Google Scholar
• GOLSTEIN DJ, WILSON MG, ASCROFT RC et al.: Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int. J. Eat. Disorder (1999) 25(1):19-27.
   PubMed Web of Science ®Google Scholar
• FLUOXETINE BULIMIA NERVOSA COLLABORATIVE STUDY GROUP: Fluoxetine in the treatment of bulimia nervosa. Archives of General Psychiatry (1992) 49:139-147.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, WILSON MG, THOMPSON VL, POTVIN JH, RAMPEY AH Jr: Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br. J. Psychiatry (1995) 166(5):660-666.
   PubMed Web of Science ®Google Scholar
• HORNE RL, FERGUSON JM, POPE HG et al.: Treatment of bulimia nervosa with bupropion: A multi-centre controlled trial. J. Clin. Psychiatry (1988) 49:262-266.
   PubMed Web of Science ®Google Scholar
• HARTMAN BK, FARIS PL, KIM SW et al.: Treatment of bulimia nervosa with ondansetron. Arch. Gen. Psychiatry (1977) 54(10):969-970.
   Google Scholar
• FARIS PL, KIM SW, MELLER WH, GOODALE RL et al.: Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa a randomized, double-blind trial. Lancet (2000) 355:792-797.
   PubMed Web of Science ®Google Scholar
• MCELROY S, ARNOLD L, SHAPIRA N et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160:255-261.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, GILLIS JC, DAVIS R: Topiramate: a review of its pharmacohynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs (1997) 54:752-773.
   PubMed Web of Science ®Google Scholar
• BARBEE JG: Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int. J. Eat. Disord. (2003) 33(4):468-472.
   PubMed Web of Science ®Google Scholar
• HOOPES SP, REIMHERR FW, HEDGES DW et al.: Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge purge measures. J. Clin. Psychiatry (2003) 64(11):1335-1341.
   PubMed Web of Science ®Google Scholar
• HEDGES DW, REIMHERR FW, HOOPES SP et al.: Treatment of bulimia nervosa with topiramate in a randomized, double-blind placebo-controlled trial, part 2: improvement in psychiatric measures. J. Clin. Psychiatry (2003) 64(12):1449-1454.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, LANDEN M, ERIKSSON T, BERGMAN L, ERIKSSON E: Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J. Clin. Psychopharmacol. (2005) 25(1):85-88.
   PubMed Web of Science ®Google Scholar
• SUNDBLAD C, BERGMAN L, ERIKSSON E: High levels of free testosterone in women with bulimia nervosa. Acta Psychiatr. Scand. (1994) 90(5):397-398.
   PubMed Web of Science ®Google Scholar
• DUMOULIN SC, DE GLISEZINSKI I, SAINT-MARTIN F et al.: Hormonal changes related to eating behavior in oligomenorrheic women. J. Endocrinol. (1996) 135:328-334.
   Web of Science ®Google Scholar
• COTRUFO P, MONTELEONE P, D’ISTRIA M et al.: Aggressive behavioral characteristics and endogenous hormones in women with bulimia nervosa. Neuropsychobiology (2000) 42:58-61.
   PubMed Web of Science ®Google Scholar
• MORGAN JF, MCCLUSKEY SE, BRUNTON JN et al.: Polycystic ovarian morphology and bulimia nervosa: a 9-year follow-up study. Fertil. Steril. (2002) 77:928-931.
   PubMed Web of Science ®Google Scholar
• EL-GIAMAL N, DE ZWAAN M, BAILER U et al.: Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int. Clin. Psychopharmacol. (2000) 15(6):351-356.
   PubMed Web of Science ®Google Scholar
• FASSINO S, DAGA GA, BOGGIO S, GARZARO L, PIIERO A: Use of reboxetine in bulimia nervosa: a pilot study. J. Psychopharmacol. (2004) 18(3):423-428.
   PubMed Web of Science ®Google Scholar
• FAHY TA, EISLER I, RUSSELL FM: A placebo-controlled trial of d-fenfluramine in bulimia nervosa. Br. J. Psychiatry (1993) 162:597-603.
   PubMed Web of Science ®Google Scholar
• RUSSELL GFM, CHECKLEY SA, FELDMAN J, EISLER I: A controlled trial of d-fenfluramine in bulimia nervosa. Clin. Neuropharmacol. (1988) 11:S146-S159.
   PubMed Web of Science ®Google Scholar
• HSU LK, CLEMENT L, SANTHOUSE R, JU ES: Treatment of bulimia nervosa with lithium carbonate: a controlled study. J. Nerv. Ment. Dis. (1991) 179:351-355.
   PubMed Web of Science ®Google Scholar
• WERMUTH BM, DAVIS KL, HOLLISTER LE: Phenytoin treatment of the binge eating syndrome. Am. J. Psychiatry (1977) 134:1249-1253.
   PubMed Web of Science ®Google Scholar
• SOKOL MS, GRAY NS, GOLDSTEIN A, KAYE WH: Methylphrenidate treatment for bulimia nervosa associated with a cluster B personality disorder. Int. J. Eat. Disord. (1999) 25(2):233-237.
   PubMed Web of Science ®Google Scholar
• EL-GIAMAL N, DE ZWAAN M, BAILER U, STRNAD A, SCHUSSLER P, KASPER S: Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. Eur. Neuropsychopharmacol. (2003) 13(2):73-79.
   PubMed Web of Science ®Google Scholar
• INGOIN-APFELBAUM L, APFELBAUM M: Naltrexone and bulimic symptoms. Lancet (1987) 2:1087-1088.
   Google Scholar
• MITCHELL JE, CHRISTENSON G, JENNINGS J et al.: A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in patients with normal weight bulimia. J. Clin. Psychopharmacol. (1989) 9:94-97.
   PubMed Web of Science ®Google Scholar
• ROMANO MANO SJ, HALMI KA, SARKAR NP, KOKE SC, LEE JS: A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am. J. Psychiatry (2002) 159(1):96-102.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, DE ZWAAN M, ROERIG JL: Drug therapy for patients with eating disorders. Curr. Drug Targets CNS Neurol. Disord. (2003) 2(1):17-29.
   PubMedGoogle Scholar
• MCELROY SL, ARNOLD LM, SHAPIRA NA et al.: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160:255-261.
   PubMed Web of Science ®Google Scholar
• MCELROY S, SHAPIRA N, ARNOLD LM et al.: Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J. Clin. Psychiatry (2004) 65:1463-1469.
   PubMed Web of Science ®Google Scholar
• APPOLINARIO JC, BACALTCHUK J, SICHIERI R et al.: A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch. Gen. Psychiatry (2003) 60(11):1109-1116.
   PubMed Web of Science ®Google Scholar
• RYAN DH, KAISER P, BRAY GA: Sibutramine: a novel new agent for obesity treatment. Obes. Res. (1995) 3(Suppl. 4):553S-559S.
   PubMedGoogle Scholar
• BRAY GA, RYAN DH, GORDON D, HEIDINGSFELDER S, CERISE F, WILSON K: A double-blind randomized placebo-controlled trial of sibutramine. Obes. Res. (1996) 3:263-270.
   Google Scholar
• JAMES WPT, ASTRUP A, FINER N et al.: Effects of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Lancet (2000) 356:219-225.
   PubMed Web of Science ®Google Scholar
• MCELROY SL, KOTWAL R, HUDSON JI, NELSON EB, KECK PE: Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J. Clin. Psychiatry (2004) 65:50-56.
   PubMed Web of Science ®Google Scholar
• LEPPIK IE: Zonisamide: a novel antiepileptic agent. Today’s Therapeutic Trends (1999) 17:181-195.
   Google Scholar
• FAUGHT E, AYALA R, MONTOURIS GG et al.: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology (2001) 57:1774-1779.
   PubMed Web of Science ®Google Scholar
• LEE BI: Zonisamide: adverse effects. In: Antileptic Drugs, 5th edn. RH Levy, BS Meldrum et al. (Eds.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):892-898.
   Google Scholar
• GADDE KM, FRANCISCY DM, WAGNER HR et al.: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA (2003) 289:1820-1825.
   PubMed Web of Science ®Google Scholar
• GRILO CM, MASHEB RM, SALANT SL: Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol. Psychiatry (2005) 57(10):1193-1201.
   PubMed Web of Science ®Google Scholar
• GOLAY A, LAURENT-JACCARD A, HABICHT F et al.: Effect of orlistat in obese patients with binge eating disorder. Obes. Res. (2005) 13(10):1701-1708.
   PubMedGoogle Scholar
• BAUMANN CR, BASSETTI CL: Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol. (2005) 4(10):673-682.
   PubMed Web of Science ®Google Scholar
• ADAM JA, MENHEERE PP, VAN DIELEN FM, SOETERS PB, BUURMAN WA, GREVE JW: Decreased plasma orexin-A levels in obese individuals. Int. J. Obes. Relat. Metab. Disord. (2002) 26(2):274-276.
   PubMed Web of Science ®Google Scholar
• EHRSTROM M, GUSTAFSSON T, FINN A et al.: Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distributin of orexin and orexin receptors in the gut and pancreas in man. J. Clin. Endocrinol. Metab. (2005) 90(4):2370-2377.
   PubMed Web of Science ®Google Scholar
• Acetelion R&D Day 2003. Acetelion Ltd Company Presentation (2003).
   Google Scholar
• Obesity, NIDDM, Adipogenesis and Insulin Resistence. IBC’s Ninth International Conference (Part III) – IDdB Meeting Report. R Watt, London, UK (2000).
   Google Scholar
• NAVEILHAN P, HASSANI H, CANALS J et al.: Normal feeding behavior, body weight, and leptin response require the neuropeptide Y Y2 receptor. Nat. Med. (1999) 5(10):1188-1193.
   PubMed Web of Science ®Google Scholar
• GRANDT D, SCHIMICZEK M, BEGLINGER C et al.: Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY1-36 and PYY3-36. Regul. Pept. (1994) 51(2):151-159.
   PubMed Web of Science ®Google Scholar
• GRANDT D, SCHIMICZEK M, STRUK K et al.: Characterization of two form of peptide YY, PYY (1-36) and PYY (3-36), in the rabbit. Peptide (1994) 15:815-820.
   PubMed Web of Science ®Google Scholar
• BATTERHAM RL, BLOOM SR: The gut hormone peptide YY regulates appetite. Ann. NY Acad. Sci. (2003) 994:162-168.
   PubMed Web of Science ®Google Scholar
• BATTERHAM R, COWLEY M, SMALL C et al.: Gut Hormone PYY3-36 physiologically inhibits food intake. Nature (2002) 418:650-654.
   PubMed Web of Science ®Google Scholar
• GUSTAFSON EL, SMITH KE, DURKIN MM et al.: Distribution of the neuropeptide Y Y2-receptor mRNA in rat central nervous system. Brain Res. Mol. Brain Res. (1997) 46:223-235.
   PubMedGoogle Scholar
• RICHARD D, LIN Q, TIMOFEEVA E: The corticotrophin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance. Eur. J. Pharmacol. (2002) 440(2-3):189-197.
   PubMed Web of Science ®Google Scholar
• HASHIMOTO K, NOISHIYAMA M, TANAKA Y et al.: Urocortins and corticotrophin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides (2004) 25(10):1711-1721.
   PubMed Web of Science ®Google Scholar
• Annual Report 2000 – Neuroscience Bioscience. Neurocrine Biosciences, Inc. Annual Report (2000).
   Google Scholar
• SCHLICKER E, MALINOWSKA B, KATMANN M, GOTHERT M: Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fund. Clin. Pharm. (1994) 8:128-137.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, DIEHL MS, FAGHIH R et al.: In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists. Basic Clin. Pharmacol. Toxicol. (2004) 95(3):144-152.
   PubMed Web of Science ®Google Scholar
• NALWALK J, TEDFORD CE, FREDERICKSON RCA et al.: Effects of H3 receptor antagonists on histamine (HA) release in the hypothalamus and on the regulation of appetite. Society of Neuroscience Abstracts (1997):23.
   Google Scholar
• WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86(12):5992.
   PubMed Web of Science ®Google Scholar
• VAN DER LELY AJ, TSCHOP M, HEIMAN ML, GHIGO E: Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. (2004) 25(3):426-457.
   PubMed Web of Science ®Google Scholar
• TROISI A, DI LORENZO G, LEGA I et al.: Plasma ghrelin in anorexia, bulimia, and binge-eating disorder: relations with eating patterns and circulating concentrations of cortisol and thyroid hormones. Neuroendocrinology (2005) 81(4):259-266.
   PubMed Web of Science ®Google Scholar
• OTTO B, CUNTZ U, FRUEHAUF E et al.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. (2001) 145(5):669-673.
   PubMed Web of Science ®Google Scholar
• MONTELEONE P, FABRAZZO M, TORTORELLA A, MARTIADIS V, SERRITELLA C, MAJ M: Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. Psychoneuroendocrinology (2005) 30(3):243-250.
   PubMed Web of Science ®Google Scholar
• GHIGO E, BROGLIO F, ARVAT E, MACCARIO M, PAPOTTI M, MUCCIOLI G: Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin. Endocrinol. (Oxf) (2005) 62(1):1-17.
   PubMed Web of Science ®Google Scholar
• NIJENHUIS WA, OOSTEROM J, ADAN RA: AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol. Endocrinol. (2001) 15(1):164-171.
   PubMed Web of Science ®Google Scholar
• SCHIOTH HB, LAGERSTROM MC, WATANOBE H et al.: Functional role, structure, and evolution of the melanocortin-4 receptor. Ann. NY Acad. Sci. (2003) 994:74-83.
   PubMed Web of Science ®Google Scholar
• BAYS HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. (2004) 12:1197-1211.
   PubMedGoogle Scholar
• HU B, JENNINGS LL: Orally bioavailable β3-adrenergic receptor agonists as potential therapeutic agents for obesity and Type 2 diabetes mellitus. Prog. Med. Chem. (2003) 41:167-194.
   PubMedGoogle Scholar
• BAILER UF, PRICE JC, MELTZER CC: Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. Neuropsychopharmacology (2004) 29(6):1143-1155.
   PubMed Web of Science ®Google Scholar
• TORSELLO A, LUONI M, SCHWEIGER F et al.: Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release. Eur. J. Pharmacol. (1998) 360:123-129.
   PubMed Web of Science ®Google Scholar
• HILL K, BUCUVALAS J, MCCLAIN C: Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J. Child Adolesc. Psychopharmacol. (2000) 10:3-8.
   PubMed Web of Science ®Google Scholar
• BROBERGER C: Brain regulation of food intake and appetite: molecules and networks. J. Int. Med. (2005) 258:301-327.
   PubMed Web of Science ®Google Scholar
• FISMAN S, STEELE M, SHORT J, BYRNE T, LAVALLEE C: Case study: anorexia nervosa and autistic disorder in an adolescent girl. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:937-940.
   PubMed Web of Science ®Google Scholar
• HANSEN L: Olanzapine in the treatment of anorexia nervosa. Br. J. Psychiatry (1999) 175:592.
   PubMed Web of Science ®Google Scholar
• JENSEN VS, MEJLHEDE A: Anorexia nervosa: treatment with olanzapine. Br. J. Psychiatry (2000) 177:87.
   PubMed Web of Science ®Google Scholar
• LA VIA MC, GRAY L, KAYE WH: Case reports of olanzapine treatment of anorexia nervosa. Int. J. Eat. Disord. (2000) 27:363-366.
   PubMed Web of Science ®Google Scholar
• NEWMAN-TOKER J: Risperidone in anorexia nervosa. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:937-940.
   Google Scholar
• GASKILL JA, TREAT TA, MCCABE EB, MARCUS MD: Does olanzapine affect the rate of weight gain among patients inpatients with eating disorders? Eat. Disord. Rev. (2001) 12(6):1-2.
   Google Scholar
• MEHLER C, WEWETZER C, SCHULZE W, WARNKE A, THEISEN F, DITTMANN RW: Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur. Child Adolesc. Psychiatry (2001) 10:151-157.
   PubMed Web of Science ®Google Scholar
• RUGGIERO GM, LAINI V, MAURI MC: A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog. Neuropsychopharmacol. Biol. Psychiat. (2001) 25:1049-1059.
   PubMed Web of Science ®Google Scholar
• CARVER AE, MILLER S, HAGMAN J, SIGEL E: The use of risperidone for the treatment of anorexia nervosa. Academy of Eating Disorders Annual Meeting. Boston, USA (2002).
   Google Scholar
• POWERS PS, SANTANA CA, BANNON YS: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord. (2002) 32:146-154.
   PubMed Web of Science ®Google Scholar
• BOACHIE A, GOLDFIELD GS, SPETTIQUE W: Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int. J. Eat. Disord. (2003) 33(1):98-103.
   PubMed Web of Science ®Google Scholar
• BARBARICH NC, MCCONAHA CW, GASKILL J et al.: An open trial of olanzapine in anorexia nervosa. J. Clin. Psychiatry (2004) 65:1480-1482.
   PubMed Web of Science ®Google Scholar
• POWERS PS, SANTANA C: Available pharmacological treatments for anorexia nervosa. Expert Opin. Pharmacother. (2004) 5(11):2287-2292.
   PubMed Web of Science ®Google Scholar